Literature DB >> 8032856

Autosomal dominant cerebellar ataxia with pigmentary macular dystrophy. A clinical and genetic study of eight families.

T P Enevoldson1, M D Sanders, A E Harding.   

Abstract

We describe 54 members of eight families with a distinct autosomal dominant cerebellar ataxia associated with visual failure secondary to a pigmentary macular dystrophy. The presenting symptom was ataxia in two-thirds of patients and visual failure or both in the remainder. The macular abnormalities were often subtle in early cases, even in some with moderately reduced visual acuity. Other neurological features included pyramidal tract signs and a supranuclear ophthalmoplegia with progressive saccadic palsy. Ages of onset and clinical course were very variable, even within families, and included a rapidly progressive, infantile-onset phenotype. Pedigree analysis showed the existence of non-manifesting obligate carriers and anticipation in the offspring of affected fathers; transmission of the disease to severe, infantile-onset cases was always from an affected father. Similar genetic phenomena have been reported in myotonic dystrophy and Huntington's disease and it is likely that the gene mutation in this condition will similarly consist of an unstable trinucleotide repeat expansion.

Entities:  

Mesh:

Year:  1994        PMID: 8032856     DOI: 10.1093/brain/117.3.445

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  26 in total

Review 1.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

2.  Pigmentary macular dystrophy in spinocerebellar ataxia type 1.

Authors:  Y Saito; K Matsumura; S Shimizu; Y Ichikawa; K Ochiai; J Goto; S Tsuji; T Shimizu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11       Impact factor: 10.154

3.  Spinocerebellar ataxia type 7 presenting as Stargardt's disease.

Authors:  Georgios Tsivgoulis; Sofia Vassilopoulou; Konstntinos Rallis; Nikolaos Markomichelakis; Konstantinos Spengos
Journal:  J Neurol       Date:  2007-12-20       Impact factor: 4.849

4.  Somatic instability of expanded CAG repeats of ATXN7 in Japanese patients with spinocerebellar ataxia type 7.

Authors:  Satoshi Katagiri; Takaaki Hayashi; Tomokazu Takeuchi; Hisashi Yamada; Tamaki Gekka; Kiyokazu Kawabe; Akira Kurita; Hiroshi Tsuneoka
Journal:  Doc Ophthalmol       Date:  2015-02-03       Impact factor: 2.379

Review 5.  The inherited ataxias and the new genetics.

Authors:  S R Hammans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

6.  A comprehensive clinical and genetic study of a large Mexican population with spinocerebellar ataxia type 7.

Authors:  L Velázquez-Pérez; C M Cerecedo-Zapata; O Hernández-Hernández; E Martínez-Cruz; Y S Tapia-Guerrero; R González-Piña; J Salas-Vargas; R Rodríguez-Labrada; R Gurrola-Betancourth; N Leyva-García; B Cisneros; J J Magaña
Journal:  Neurogenetics       Date:  2014-10-16       Impact factor: 2.660

7.  Spinocerebellar ataxia Type 7: clinical and genetic study of a new Moroccan family (case report).

Authors:  Fatima Zahra Bouzid; Maria Mansouri; Chaikhy Abdelaziz; Nisrine Louhab; Sablonniere Bernard; Isabelle Strubi-Vuillaume; Kenza Dafir; Nisrine Aboussair
Journal:  Pan Afr Med J       Date:  2021-02-12

8.  Molecular and clinical study of 18 families with ADCA type II: evidence for genetic heterogeneity and de novo mutation.

Authors:  P Giunti; G Stevanin; P F Worth; G David; A Brice; N W Wood
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

Review 9.  Eye movements in patients with neurodegenerative disorders.

Authors:  Tim J Anderson; Michael R MacAskill
Journal:  Nat Rev Neurol       Date:  2013-01-22       Impact factor: 42.937

10.  Spinocerebellar ataxia type 7: clinical course, phenotype-genotype correlations, and neuropathology.

Authors:  Laura C Horton; Matthew P Frosch; Mark G Vangel; Carol Weigel-DiFranco; Eliot L Berson; Jeremy D Schmahmann
Journal:  Cerebellum       Date:  2013-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.